Texas Urologist Will Head National Cancer Institute

Cancer leaders embraced President George W. Bush's appointment Dec. 6 of Texas urologist Andrew von Eschenbach to head the National Cancer Institute (NCI). In no uncertain terms, they praised von Eschenbach's political know-how, consensus-building skills, and openness to promoting all facets of a nationwide cancer agenda. Trish Strangmeyer PhotographyAndrew von Eschenbach A urologic surgeon, von Eschenbach directed the Genitourinary Cancer Center and Prostate Cancer Research Center at the Univer

Written byLaura Newman
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

A urologic surgeon, von Eschenbach directed the Genitourinary Cancer Center and Prostate Cancer Research Center at the University of Texas M.D. Anderson Cancer Center in Houston. When his appointment was announced, von Eschenbach was also president-elect of the American Cancer Society and a founder of the National Dialogue on Cancer, a national forum and public-private partnership devoted to spearheading a national cancer agenda. The National Dialogue on Cancer was established in 1998 in conjunction through the American Cancer Society, American Society of Clinical Oncology, the Centers for Disease Control and Prevention, industry, and other partners. President Bush and First Lady Laura Bush chair the group, U.S. Sen. Diane Feinstein (D-Calif.) is vice chair, and Tom Ridge, former Pennsylvania governor and now director of homeland security at the White House, was an early collaborating partner. Although to a certain extent, people acknowledged that von Eschenbach, a close confidante of the Bush ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies